Colorectal Cancer — An Interview with Dr John Strickler on Molecular Residual Disease Analysis

Failed to add items

Sorry, we are unable to add the item because your shopping cart is already at capacity.

Please try again later

Please try again later

Please try again later

Listen for free

View show details

Featuring an interview from Dr John Strickler, including the following topics:

Prognostic value of molecular residual disease (MRD) as detected by circulating tumor DNA (ctDNA) and optimal incorporation of MRD assays into the care of patients with colorectal cancer (0:00)
Potential use of MRD assays for patients with microsatellite instability (MSI)-high localized colorectal cancer or those with delayed progression or metastatic disease (16:09)
Tumor-informed MRD assays under clinical development (20:36)
Predictive role of ctDNA in Stage III colon cancer treated with celecoxib; effect of low-dose aspirin on response to celecoxib in patients with PI3K pathway alterations (24:19)
Case: A man in his late 50s with resected Stage IIA colon cancer (30:06)
Case: A woman in her late 40s with Lynch syndrome and MSI-H colon cancer with a solitary, small hepatic metastasis (34:57)
MRD as a future clinical trial endpoint for solid tumors; increasing incidence of colorectal cancer in younger people (40:24)
Antibody-drug conjugates in the treatment of colorectal cancer (45:13)
Perspectives on promising areas of clinical research in colorectal cancer (48:23)

CME information and select publications

No reviews yet